NVAX Stock Price: Novavax continues to rise after rival coronavirus vaccine is halted

NASDAQ:NVAX gains 2.22% on Thursday despite broader market dip.
News of AstraZeneca halting its COVID-19 vaccine study has boosted other rivals in the industry.
Novavax has dropped nearly half of its market cap during the last month, enticing bargain investors.

Stocks Reporter FXStreet

NASDAQ:NVAX has gained where its rivals have faltered as the race for the coronavirus vaccine took a turn for the worse when AstraZeneca (NYSE:AZN) announced it was halting its final phase clinical study due to adverse effects reported in patients. Shares of Novavax jumped over 15% during the next few days as investors rushed to secure their stakes in AstraZeneca’s chief rivals. The small boost was nice for Novavax investors but the biotech stock is still down nearly 45% over the past 30 days and is down over 50% from its 52-week highs of $189.40 – although shares are still up an astounding 1500% over the last year.

Industry rivals like Moderna (NASDAQ:MRNA), Pfizer (NYSE:PFE), and BioNtech (NASDAQ:BNTX) all benefited from AstraZeneca’s falter, although each stock has been up and down until the end of the week. Some analysts are speaking about if a Biden Administration would hand out the same loans to these biotech companies for a coronavirus vaccine but with AstraZeneca’s failure, the desperation for a vaccine has heightened.

NVAX Stock News

Investors should act fast if they believe NVAX has a chance at taking over the lead in Operation Warp Speed. Shares have settled and Novavax also has a flu vaccine called NanoFlu that is coming down the pipe that could translate to another revenue stream moving forward. NanoFlu is getting ready to be submitted for final FDA approval which could mean that Novavax and its investors may not have to rely on a successful coronavirus vaccine for the stock to return to its previous levels.

Author

Stocks Reporter

FXStreet

GBP/USD off highs, back to 1.3620

GBP/USD remains slightly on the defensive at the end of the week, receding to the low 1.3600s after hitting fresh tops past 1.3670 earlier in the day. Cable’s correction comes after two daily gains in a row and amid a tepid advance in the Greenback, while poor UK data also accompany the downside.

EUR/USD treads water below 1.1700

EUR/USD now trades with modest losses around 1.1670 following another unsuccessful atempt to advance past 1.1700 the figure in a convincing fashion. The pair’s decline follows a maginal rebound in the US Dollar as market participants continue to assess recent US data as well as developments from the US bond market.

Gold trims gains, recedes to the sub-$4,600 area

Gold rapidly leaves behind Thursday’s inconclusive price action and advances markedly on Friday, briefly surpassing the $4,600 mark per troy ounce to hit three-month peaks. Meanwhile, the precious metal’s solid performance comes despite marginal gains in the buck coupled with another day of rising US Treasury yields across the curve.

Crypto Today: Bitcoin, Ethereum, XRP bulls accelerate rally amid rising ETF inflows

The cryptocurrency market remains bullish on Friday, led by Bitcoin’s surge above $77,000. Altcoins, including Ethereum and Ripple, mirror BTC’s positive outlook, trading near $2,400 and $1.35, respectively.

Week ahead – Fed’s Jackson Hole and Nvidia earnings to dictate markets

Kevin Warsh to make his Jackson Hole debut amid confusing messaging. But a major hawkish surprise unlikely after bond market intervention. Nvidia earnings to also determine market direction as stock rally cools.

$20 billion offered, $2 billion taken: Why Treasury doubled its buyback cap

The US Treasury moved off its own calendar on Wednesday, and that is the part worth sitting with. At 12:32 GMT, the department said it would at least double the size of liquidity support buyback operations in the 10-year to 20-year and 20-year to 30-year sectors, lifting the maximum from $2 billion per operation to at least $4 billion, effective September 9 and running to November 4.